Compugen is a clinical-stage therapeutic discovery and development company utilizing its predictive computational discovery capabilities to identify drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Co.'s immuno-oncology pipeline consists of four clinical stage programs, COM701, which is an anti-PVRIG antibody, for the treatment of solid tumors; COM902, which is a therapeutic antibody targeting TIGIT; Bapotulimab, which is an antibody targeting ILDR2; and AZD2936, which is an anti-TIGIT/PD-1 bispecific antibody with a TIGIT component that is derived from Co.'s COM902 program. The CGEN YTD return is shown above.
The YTD Return on the CGEN YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether CGEN YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CGEN YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|